JAN 26, 2016 08:00 AM PST
WEBINAR: Concordance of PTEN gene status in circulating tumor cells and tumor tissue from mCRPC patients
SPONSORED BY: Epic Sciences
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
9 32 7516

Speakers:
  • Research Scientist, Genentech
    Biography
      Edith Szafer-Glusman. Ph.D. is a research scientist with solid academic and industry background in cancer cell biology and tumor metabolism. Her current work at Genentech includes developing oncology diagnostics strategies that involve identification and analysis of circulating tumor cells. Dr. Szafer- Glusman received her Ph.D. from Technion-Israel Institute of Technology and holds a Master's degree in biochemistry from Weizmann Institute of Science.

    Abstract:
    DATE: January 26th, 2016
    TIME: 8am pacific, 11am eastern

    PTEN gene loss occurs frequently in castration-resistant prostate cancer (CRPC) and may drive progression through activation of the PI3K/AKT pathway. Here, we developed a novel CTC-based assay to determine PTEN status and examined the correlation between PTEN status in CTCs and matched tumour tissue samples. PTEN gene status in CTCs was evaluated on an enrichment-free platform (Epic Sciences) by fluorescence in situ hybridisation (FISH). PTEN status in archival and fresh tumour tissue was evaluated by FISH and immunohistochemistry.  Peripheral blood was collected from 76 patients. Matched archival and fresh cancer tissue was available for 48 patients. PTEN gene status detected in CTCs was concordant with PTEN status in matched fresh tissues and archival tissue in 32 of 38 patients (84%) and 24 of 39 patients (62%), respectively. CTC counts were prognostic (continuous, P ¼ 0.001). PTEN loss in CTCs associated with worse survival in univariate analysis (HR 2.05; 95% CI 1.17–3.62; P ¼ 0.01) and with high lactate dehydrogenase (LDH) in metastatic CRPC patients. Our results illustrate the potential use of CTCs as a non-invasive, real-time liquid biopsy to determine PTEN gene status. The prognostic and predictive value of PTEN in CTCs warrants investigation in CRPC clinical trials of PI3K/AKT-targeted therapies.
     

    Show Resources
    Loading Comments...